Please login to the form below

Not currently logged in
Email:
Password:

Pfizer takes aim at UK’s health tech industry

Offers start-ups a share of a £56k grant

Pfizer

Pharma giant Pfizer has launched a new initiative that is intended to invest in start-up companies based in the UK.

Pfizer Healthcare Hub: London will offer start-ups a chance to compete for a share of a grant worth £56k and a year-long programme of support, helping the companies navigate the UK’s health system.

With this move, Pfizer has recognised that technology, including devices, apps, wearables, artificial intelligence and virtual reality, plays an increasing role in delivering and improving healthcare and the company aims to “support and accelerate innovation in this area”.

Erik Nordkamp, managing director, Pfizer UK, said: “I’m delighted that we’ll be launching the Pfizer Healthcare Hub here in the UK.

“We live in a country that is already a centre for original thinking and innovation within healthcare and our goal is to accelerate the success of the brightest start-ups in this field and help them make a difference to patients.”

The successful start-ups will benefit from access to Pfizer’s network of global partners, including the NHS.

Dr Hamish Graham, manager for Pfizer Healthcare Hub: London, said: “The healthcare hub will provide a platform for start-ups to harness Pfizer’s global network, enabling them to get access to our expertise, understanding and guidance.

“We hope, with our support, that they’ll be able to reach their goals and get their innovations adopted within the health service.”

The London Hub is the latest in a string of existing centres in New York, Berlin and Tel Aviv.

New hubs are also being launched simultaneously in Stockholm, Sydney and Toronto.

Article by
Gemma Jones

25th April 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics